Paula Rodriguez Otero, MD, PhD, University Clinic of Navarra, Pamplona, Spain, comments on the updated follow-up results of the TRIMM-2 study (NCT04108195) investigating talquetamab and daratumumab in patients with relapsed/refractory (R/R) multiple myeloma. The study included heavily pretreated patients, including many that had received prior BCMA-directed therapy. The study's results indicated a high response rate (RR), a high proportion of patients achieving a very good partial response (VGPR) or better, and promising progression-free survival (PFS) data. The safety profile was consistent with that of daratumumab and talquetamab monotherapy. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
